AT177 — Topline data
2027
AT177 is currently in IND-enabling studies, with a proof-of-concept clinical trial planned for 2027.Source filing
ADIL biotech catalysts & pipeline
ADIAL PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
AT177 — IND submission
Q2 2027
AT177 is currently in IND-enabling studies, with an investigational new drug ("IND") filing planned for the second quarter of 2027, initiation of a Phase 1a single- and multiple-ascending-dose ("SAD/MAD") clinical trial planned to commence in the second half of 2027, followed by a Phase 1b proof-of-concept study in UC patients.Source filing
AT177 — Initial data
H1 2028
As of the date of this Quarterly Report on Form10-Q, we have completed a GLP toxicology in rats evaluating AT177, received pre-IND feedback from the U.S. Food and Drug Administration (the "FDA"), and are advancing AT177 through IND-enabling studies, with an IND planned for the second quarter of 2027.Source filing